Results 181 to 190 of about 157,262 (340)

Complete financial disclosure for improved transparency in nutrition communication. [PDF]

Front Public Health
Reynolds AN, Soedamah-Muthu SS.
europepmc   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

A Multifaceted Vision of Challenges and Opportunities in Practical Artificial Photosynthesis Devices. [PDF]

Artif Photosynth
Perathoner S, Li C, Wang J, Li R, Wang W, Centi G, Romano V.   +6 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Quantifying Innovation in Stroke: Large Language Model Bibliometric Analysis. [PDF]

J Med Internet Res
Marcus A, Lockwood-Taylor G, Rueckert D, Bentley P.   +3 more
europepmc   +1 more source

Book Reviews [PDF]

, 1938

core   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Research on the development trend of global running protection equipment technology from the perspective of patent measurement. [PDF]

PLoS One
Shen Q, Liu Y, Qiang L.
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Matching Patients With Cell Surface-Targeted Clinical Trials Using Large Language Models. [PDF]

JCO Precis Oncol
Callahan SC, Chrostek MR, Rydzewski N, Bootsma M, Helzer KT, Bakhtiar H, Morris ZS, Kosoff D, Lang JM, Ma VT, Sharifi M, Zhao SG.   +11 more
europepmc   +1 more source